Gyre Therapeutics, Inc. (NASDAQ:GYRE) Given Average Rating of “Hold” by Brokerages

Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) have been assigned a consensus rating of “Hold” from the five analysts that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $17.00.

Several brokerages have issued reports on GYRE. Jefferies Financial Group initiated coverage on Gyre Therapeutics in a research note on Friday, October 10th. They set a “buy” rating and a $16.00 price objective on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Gyre Therapeutics in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Gyre Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 15th. HC Wainwright started coverage on Gyre Therapeutics in a research note on Tuesday, August 26th. They set a “buy” rating and a $18.00 target price on the stock. Finally, Zacks Research raised shares of Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, November 14th.

Gyre Therapeutics Trading Down 1.5%

GYRE opened at $8.04 on Wednesday. The company has a fifty day simple moving average of $7.81 and a 200 day simple moving average of $7.80. The firm has a market cap of $774.49 million, a price-to-earnings ratio of 268.09 and a beta of 1.96. Gyre Therapeutics has a twelve month low of $6.11 and a twelve month high of $14.42.

Institutional Trading of Gyre Therapeutics

A number of hedge funds have recently bought and sold shares of GYRE. State of Alaska Department of Revenue acquired a new stake in shares of Gyre Therapeutics during the third quarter valued at approximately $38,000. Bank of America Corp DE increased its position in Gyre Therapeutics by 28.8% in the 2nd quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock worth $46,000 after purchasing an additional 1,402 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Gyre Therapeutics by 84.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock worth $47,000 after purchasing an additional 2,961 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Gyre Therapeutics by 77.8% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock valued at $54,000 after acquiring an additional 3,244 shares during the last quarter. Finally, Advantage Alpha Capital Partners LP boosted its holdings in Gyre Therapeutics by 54.0% in the first quarter. Advantage Alpha Capital Partners LP now owns 13,663 shares of the company’s stock worth $105,000 after purchasing an additional 4,790 shares in the last quarter. 23.99% of the stock is owned by hedge funds and other institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.